Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

SHSE:600196 Stock Report

Market Cap: CN¥56.5b

Shanghai Fosun Pharmaceutical (Group) Management

Management criteria checks 2/4

Shanghai Fosun Pharmaceutical (Group)'s CEO is Deyong Wen, appointed in Jan 2022, has a tenure of 2.33 years. total yearly compensation is CN¥10.00M, comprised of 25.9% salary and 74.1% bonuses, including company stock and options. directly owns 0.009% of the company’s shares, worth CN¥5.22M. The average tenure of the management team and the board of directors is 2.1 years and 4.9 years respectively.

Key information

Deyong Wen

Chief executive officer

CN¥10.0m

Total compensation

CEO salary percentage25.9%
CEO tenure2.3yrs
CEO ownership0.009%
Management average tenure2.1yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

We Think You Can Look Beyond Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Lackluster Earnings

Apr 02
We Think You Can Look Beyond Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Lackluster Earnings

Is Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) A Risky Investment?

Mar 18
Is Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) A Risky Investment?

Are Investors Undervaluing Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) By 48%?

Feb 26
Are Investors Undervaluing Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) By 48%?

CEO Compensation Analysis

How has Deyong Wen's remuneration changed compared to Shanghai Fosun Pharmaceutical (Group)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

CN¥2b

Dec 31 2023CN¥10mCN¥3m

CN¥2b

Sep 30 2023n/an/a

CN¥4b

Jun 30 2023n/an/a

CN¥4b

Mar 31 2023n/an/a

CN¥4b

Dec 31 2022CN¥8mCN¥2m

CN¥4b

Compensation vs Market: Deyong's total compensation ($USD1.38M) is above average for companies of similar size in the CN market ($USD269.66K).

Compensation vs Earnings: Deyong's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


CEO

Deyong Wen (52 yo)

2.3yrs

Tenure

CN¥9,997,000

Compensation

Mr. Deyong Wen serves as Executive Director of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since August 10 2022. He has been a Non-Executive Director at Shanghai Henlius Biotech, Inc. since July 28, 20...


Leadership Team

NamePositionTenureCompensationOwnership
Kexin Wang
Executive Co-Chairman2.4yrsCN¥15.25m0.018%
CN¥ 10.3m
Yifang Wu
Executive Chairman7.8yrsCN¥12.14m0.052%
CN¥ 29.2m
Deyong Wen
Joint President2.3yrsCN¥10.00m0.0092%
CN¥ 5.2m
Xiaohui Guan
Executive Vice Chairman2.4yrsCN¥9.14m0.017%
CN¥ 9.4m
Shengli Li
Executive President & Chief Growth Officer2.3yrsno data0.0012%
CN¥ 655.2k
Rongli Feng
Executive Presidentless than a yearno data0.0043%
CN¥ 2.4m
Jing Li
Executive President and CEO of Established Medicines Manufacturing & Supply Divisionno datano data0.0043%
CN¥ 2.4m
Wang Xingli
Executive President1.3yrsno datano data
Wenjie Zhang
Executive President & Co-CEO of Innovative Drug Division1.3yrsno datano data
Xiaolei Wu
VP & CFO2.3yrsno datano data
Jia Yan
Director of the Accounting Departmentno datano datano data
Dongjiu Li
Senior Vice President & Director of Pharmaceutical Commerce Admin Station Committee3.2yrsno data0.0025%
CN¥ 1.4m

2.1yrs

Average Tenure

52yo

Average Age

Experienced Management: 600196's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kexin Wang
Executive Co-Chairman2.4yrsCN¥15.25m0.018%
CN¥ 10.3m
Yifang Wu
Executive Chairman7.8yrsCN¥12.14m0.052%
CN¥ 29.2m
Deyong Wen
Joint President1.8yrsCN¥10.00m0.0092%
CN¥ 5.2m
Xiaohui Guan
Executive Vice Chairman2.4yrsCN¥9.14m0.017%
CN¥ 9.4m
Fang Yao
Non-Executive Director13.9yrsno data0.017%
CN¥ 9.7m
Guliang Tang
Independent Non-Executive Director4.9yrsCN¥392.00kno data
Qiyu Chen
Non-Executive Director19yrsno data0.0043%
CN¥ 2.4m
Xiaoliang Xu
Non-Executive Director4.9yrsno datano data
Ling Li
Independent Non-Executive Director4.9yrsCN¥392.00kno data
Tze Shan Yu
Independent Non-Executive Director2.9yrsCN¥392.00kno data
Qian Ren
Chairman of Supervisory Committee6.3yrsno data0.00065%
CN¥ 367.1k
Quandi Wang
Independent Non-Executive Director2.9yrsCN¥392.00kno data

4.9yrs

Average Tenure

54yo

Average Age

Experienced Board: 600196's board of directors are considered experienced (4.9 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.